▶주메뉴 바로가기
▶본문 바로가기
[ THE INVESTOR ] The US prescription sales of Celltrion ’s biosimilar Inflectra rose 10 percent in April compared to the previous month, continuing a five-month upward trend since its launch in t...
[ THE INVESTOR ] Korea’s Ilyang Pharmaceutical said its leukemia drug has been found to be more effective than Novartis’ Gleevec during the final clinical studies. Ilyang’s Supect has been stati...
[ THE INVESTOR ] Genexine has been granted approval to initiate phase 1 and 2 clinical trials of its recombinant thyroid stimulating hormone GX-30 from Korea’s drug regulatory body, the company s...
[ THE INVESTOR ] Korea University Medical Center said on May 26 that it will work with SK C&C to develop an intelligence artificial system that diagnoses antibiotics for patients at hospitals by n...
[ THE INVESTOR ] JW Holdings has signed a contract with India’s Gland Pharma to supply raw materials of antibiotics drug ertapenem worth US$26 million, the company said on May 25. Under the agree...
[ THE INVESTOR ] The South Korean financial regulator has fined 14 individuals a combined 2.4 billion won (US$2.1 million) for using undisclosed information to reap illegal profits through stock tr...
[ THE INVESTOR ] Celltrion said on May 23 that it has received a nod from China’s drug regulator to initiate clinical trials of its biosimilar Remsima, clearing the first hurdle in the world’s se...
[THE INVESTOR] The Korean unit of Swiss drug giant Novartis on May 24 was slapped with a 55.9 billion won (US$49.62 million) fine and insurance coverage suspension for some of its drugs as the countr...
[ THE INVESTOR ] Korean biotech firm Seegene said May 23 that it has entered into a strategic partnership with Thermo Fisher Scientific, the world’s No. 1 maker of scientific instruments, to bri...
[ THE INVESTOR ] Green Cross is expected to see growth in exports of its plasma derivatives and vaccine products in the second half of the year, a local securities firm said on May 23. “Its quar...
[ THE INVESTOR ] DaeHwa Pharmaceutical plans to start clinical studies of its oral formulation of cancer chemotherapy medication paclitaxel in the US, an industry source said on May 22. “DaeHwa is...
[ THE INVESTOR ] Janssen Biotech, a unit of Johnson & Johnson, filed a suit against Samsung Bioepis in the United States alleging that the Korean company has violated its patent rights. The suit,...
[ THE INVESTOR ] Korean diagnostic reagents maker Green Cross Medical Science has signed an 8.05 billion won (US$7.14 million) contract with Boryung Pharmaceutical to supply dialysate solution, th...
[ THE INVESTOR ] Green Cross is seeking to issue some 100 billion won (US$88.70 million) in bonds to invest in entering overseas markets, according to industry sources on May 19. The drug maker,...
[ THE INVESTOR ] Investors are paying keen attention to Hugel , a Korean botulinum toxin maker that has recently been acquired by US private equity firm Bain Capital. On April 17, Bain agreed t...
iPhone 8 unlikely to have curved edge display: source
Egg scare eases off in stock markets
Korean mobile carriers consider legal action against cost-cutting measures
Supply bottleneck to drag on for flexible OLED panels
Peter Thiel-backed Crescendo invests W60b in Hancom
Samsung Bioepis likely to launch first Herceptin biosimilar in EU
Demand for ultra-compact EVs rises in Korea
[DECODED X] Knock, knock, knocking on Samsung's door...
![[DECODED X] Knock, knock, knocking on Samsung's door...](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=152&simg=/content/image/2017/08/16/20170816001036_0.jpg&md=20170817115735)
